Sphingolipids: players in the pathology of metabolic disease

Trends in Endocrinology and Metabolism

Volumn 20, Issue 1, 2009, Pages 34-42

  Cowart, L Ashley ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; FATTY ACID; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE;

ADIPOSE TISSUE; CATABOLISM; CELL DEATH; FATTY ACID BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID COMPOSITION; LIPID METABOLISM; LIPOGENESIS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PLEIOTROPY; PRIORITY JOURNAL; REVIEW;

ANIMALS; FATTY ACIDS; HUMANS; INSULIN RESISTANCE; METABOLIC DISEASES; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; OBESITY; SPHINGOLIPIDS;

EID: 58149144739     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2008.09.004     Document Type: Review

References (89)

1. de Ferranti S., and Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin. Chem. 54 (2008) 945-955
2. Samad F., et al. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 55 (2006) 2579-2587
3. Chavez J.A., and Summers S.A. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch. Biochem. Biophys. 419 (2003) 101-109
4. Shimabukuro M., et al. Fatty acid-induced β cell apoptosis: a link between obesity and diabetes. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2498-2502
5. Kyrou I., et al. Stress, visceral obesity, and metabolic complications. Ann. N. Y. Acad. Sci. 1083 (2006) 77-110
6. Bergman R.N., et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am. J. Med. 120 (2007) S3-S8
7. Bergman R.N., et al. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 14 (2006) 16S-19S
8. Holland W.L., and Summers S.A. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 29 (2008) 381-402
9. Unger R.H., and Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim. Biophys. Acta 1585 (2002) 202-212
10. Boden G. Pathogenesis of type 2 diabetes. Insulin resistance. Endocrinol. Metab. Clin. North Am. 30 (2001) 801-815
11. Hannun Y.A., and Obeid L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9 (2008) 139-150
12. Sud M., et al. LMSD: LIPID MAPS structure database. Nucleic Acids Res. 35 (2007) D527-D532
13. Lahiri S., and Futerman A.H. The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci. 64 (2007) 2270-2284
14. Delgado A., et al. Inhibitors of sphingolipid metabolism enzymes. Biochim. Biophys. Acta 1758 (2006) 1957-1977
15. Hannun Y.A., and Obeid L.M. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem. 277 (2002) 25847-25850
16. Sawai H., and Hannun Y.A. Ceramide and sphingomyelinases in the regulation of stress responses. Chem. Phys. Lipids 102 (1999) 141-147
17. Hannun Y.A., and Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol. 10 (2000) 73-80
18. van Meer G., and Holthuis J.C. Sphingolipid transport in eukaryotic cells. Biochim. Biophys. Acta 1486 (2000) 145-170
19. Samad F. The contribution of sphingolipids to the pathogenesis of obesity. Future Lipidol. 2 (2007) 625-639
20. Perry D.K. Serine palmitoyltransferase: role in apoptotic de novo ceramide synthesis and other stress responses. Biochim. Biophys. Acta 1585 (2002) 146-152
21. Linn S.C., et al. Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption. Biochem. Soc. Trans. 29 (2001) 831-835
22. Pewzner-Jung Y., et al. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: insights into the regulation of ceramide synthesis. J. Biol. Chem. 281 (2006) 25001-25005
23. Michel C., et al. Characterization of ceramide synthesis. A dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide. J. Biol. Chem. 272 (1997) 22432-22437
24. Hait N.C., et al. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim. Biophys. Acta 1758 (2006) 2016-2026
25. Sugiura M., et al. Ceramide kinase, a novel lipid kinase. Molecular cloning and functional characterization. J. Biol. Chem. 277 (2002) 23294-23300
26. Mitsutake S., et al. The generation and behavioral analysis of ceramide kinase-null mice, indicating a function in cerebellar Purkinje cells. Biochem. Biophys. Res. Commun. 363 (2007) 519-524
27. Tafesse F.G., et al. The multigenic sphingomyelin synthase family. J. Biol. Chem. 281 (2006) 29421-29425
28. Yang C., and Kazanietz M.G. Divergence and complexities in DAG signaling: looking beyond PKC. Trends Pharmacol. Sci. 24 (2003) 602-608
29. Villani M., et al. Sphingomyelin synthases regulate production of diacylglycerol at the Golgi. Biochem. J. 414 (2008) 31-41
30. Merrill Jr. A.H., et al. (Glyco)sphingolipidology: an amazing challenge and opportunity for systems biology. Trends Biochem. Sci. 32 (2007) 457-468
31. Alvarez-Vasquez F., et al. Simulation and evaluation of sphingolipid metabolism in S. cerevisiae. Nature 433 (2005) 425-429
32. Clarke C.J., et al. The extended family of neutral sphingomyelinases. Biochemistry 45 (2006) 11247-11256
33. Kitatani K., et al. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell. Signal. 20 (2008) 1010-1018
34. Bielawski J., et al. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39 (2006) 82-91
35. Sullards M.C., et al. Structure-specific, quantitative methods for analysis of sphingolipids by liquid chromatography-tandem mass spectrometry: "inside-out" sphingolipidomics. Methods Enzymol. 432 (2007) 83-115
36. Panjarian S., et al. De novo N-palmitoylsphingosine synthesis is the major biochemical mechanism of ceramide accumulation following p53 up-regulation. Prostaglandins Other Lipid Mediat. 86 (2008) 41-48
37. Senkal C.E., et al. Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol. Cancer Ther. 6 (2007) 712-722
38. Laviad E.L., et al. Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J. Biol. Chem. 283 (2008) 5677-5684
39. Merrill Jr. A.H., et al. Kinetics of long-chain (sphingoid) base biosynthesis in intact LM cells: effects of varying the extracellular concentrations of serine and fatty acid precursors of this pathway. Biochemistry 27 (1988) 340-345
40. Williams R.D., et al. Enzymology of long-chain base synthesis by liver: characterization of serine palmitoyltransferase in rat liver microsomes. Arch. Biochem. Biophys. 228 (1984) 282-291
41. Futerman A.H., and Hannun Y.A. The complex life of simple sphingolipids. EMBO Rep. 5 (2004) 777-782
42. El Alwani M., et al. Bioactive sphingolipids in the modulation of the inflammatory response. Pharmacol. Ther. 112 (2006) 171-183
43. Malagarie-Cazenave S., et al. Sphingolipid signalling: molecular basis and role in TNF-α-induced cell death. Expert Rev. Mol. Med. 4 (2002) 1-15
44. Lamour N.F., and Chalfant C.E. Ceramide-1-phosphate: the "missing" link in eicosanoid biosynthesis and inflammation. Mol. Interv. 5 (2005) 358-367
45. Ruvolo P.P. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol. Res. 47 (2003) 383-392
46. Snook C.F., et al. Sphingolipid-binding proteins. Biochim. Biophys. Acta 1761 (2006) 927-946
47. Taha T.A., et al. Sphingosine kinase: biochemical and cellular regulation and role in disease. J. Biochem. Mol. Biol. 39 (2006) 113-131
48. Pettus B.J., et al. Ceramide in apoptosis: an overview and current perspectives. Biochim. Biophys. Acta 1585 (2002) 114-125
49. Siskind L.J., et al. Anti-apoptotic Bcl-2 family proteins disassemble ceramide channels. J. Biol. Chem. 283 (2008) 6622-6630
50. Novgorodov S.A., et al. Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J. Biol. Chem. 280 (2005) 16096-16105
51. Taha T.A., et al. A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim. Biophys. Acta 1758 (2006) 2027-2036
52. Alvarez S.E., et al. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol. Metab. 18 (2007) 300-307
53. Alemany R., et al. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch. Pharmacol. 374 (2007) 413-428
54. Maceyka M., et al. Shooting the messenger: oxidative stress regulates sphingosine-1-phosphate. Circ. Res. 100 (2007) 7-9
55. Kluk M.J., and Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim. Biophys. Acta 1582 (2002) 72-80
56. Van Brocklyn J.R., et al. Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J. Cell Biol. 142 (1998) 229-240
57. Subramanian P., et al. Anionic lipids activate group IVA cytosolic phospholipase A2 via distinct and separate mechanisms. J. Lipid Res. 48 (2007) 2701-2708
58. Pettus B.J., et al. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J. Biol. Chem. 279 (2004) 11320-11326
59. Zhi L., et al. Sphingosine kinase 1 regulates pro-inflammatory responses triggered by TNFα in primary human monocytes. J. Cell. Physiol. 208 (2006) 109-115
60. Billich A., et al. Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: function in cell survival and IL-1β and TNF-α induced production of inflammatory mediators. Cell. Signal. 17 (2005) 1203-1217
61. Lee H., et al. Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-κB-dependent mechanism. Am. J. Physiol. Cell Physiol. 287 (2004) C1657-C1666
62. Chen X.L., et al. Sphingosine kinase-1 mediates TNF-α-induced MCP-1 gene expression in endothelial cells: upregulation by oscillatory flow. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H1452-H1458
63. Lavieu G., et al. Is autophagy the key mechanism by which the sphingolipid rheostat controls the cell fate decision?. Autophagy 3 (2007) 45-47
64. Lavieu G., et al. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J. Biol. Chem. 281 (2006) 8518-8527
65. Scarlatti F., et al. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J. Biol. Chem. 279 (2004) 18384-18391
66. Modi H.R., et al. Ageing-induced alterations in lipid/phospholipid profiles of rat brain and liver mitochondria: implications for mitochondrial energy-linked functions. J. Membr. Biol. 221 (2008) 51-60
67. Di Paola M., et al. Ceramide interaction with the respiratory chain of heart mitochondria. Biochemistry 39 (2000) 6660-6668
68. Newsholme P., et al. Life and death decisions of the pancreatic β-cell: the role of fatty acids. Clin. Sci. (Lond.) 112 (2007) 27-42
69. Kelpe C.L., et al. Palmitate inhibition of insulin gene expression is mediated at the transcriptional level via ceramide synthesis. J. Biol. Chem. 278 (2003) 30015-30021
70. 2+-dependent exocytosis in rat pancreatic β-cells. Diabetes 51 (2002) 2514-2521
71. Laychock S.G., et al. Sphingosine 1-phosphate affects cytokine-induced apoptosis in rat pancreatic islet β-cells. Endocrinology 147 (2006) 4705-4712
72. Chavez J.A., et al. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J. Biol. Chem. 278 (2003) 10297-10303
73. Stratford S., et al. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J. Biol. Chem. 279 (2004) 36608-36615
74. Holland W.L., et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5 (2007) 167-179
75. Pickersgill L., et al. Key role for ceramides in mediating insulin resistance in human muscle cells. J. Biol. Chem. 282 (2007) 12583-12589
76. Watt M.J., et al. Ciliary neurotrophic factor prevents acute lipid-induced insulin resistance by attenuating ceramide accumulation and phosphorylation of c-Jun N-terminal kinase in peripheral tissues. Endocrinology 147 (2006) 2077-2085
77. Itani S.I., et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 51 (2002) 2005-2011
78. Yu C., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277 (2002) 50230-50236
79. Straczkowski M., et al. Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 53 (2004) 1215-1221
80. Adams II J.M., et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53 (2004) 25-31
81. Tagami S., et al. Ganglioside GM3 participates in the pathological conditions of insulin resistance. J. Biol. Chem. 277 (2002) 3085-3092
82. Kabayama K., et al. TNFα-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement of ganglioside GM3. Glycobiology 15 (2005) 21-29
83. Shah C., et al. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J. Biol. Chem. 283 (2008) 13538-13548
84. Heilbronn L.K., and Campbell L.V. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr. Pharm. Des. 14 (2008) 1225-1230
85. Wu D., et al. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J. Immunol. 179 (2007) 4829-4839
86. Stover T.C., et al. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials 29 (2008) 359-369
87. Chen Y., et al. Imaging MALDI mass spectrometry using an oscillating capillary nebulizer matrix coating system and its application to analysis of lipids in brain from a mouse model of Tay-Sachs/Sandhoff disease. Anal. Chem. 80 (2008) 2780-2788
88. Cazzolli R., et al. A role for protein phosphatase 2A-like activity, but not atypical protein kinase Cζ, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes 50 (2001) 2210-2218
89. Skovbro M., et al. Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. Diabetologia 51 (2008) 1253-1260